Main Article Content
COVID-19, vaccine effectiveness, health care workers
Background and aim:
Randomized controlled trials have shown that mRNA vaccines are highly effective in preventing SARS-CoV2 infection. We conducted a study to assess the real-world effectiveness of mRNA vaccines (Pfizer-BioNTech or Moderna) in preventing all and symptomatic SARS-CoV2 infections and COVID-19 related hospitalizations in the staff of the Bologna Health Trust (HT), Italy
We followed up retrospectively 9839 staff of the Bologna HT from December 27, 2020 to April 3, 2020 and calculated the effectiveness in partially and fully vaccinated subjects by applying a multivariable Cox proportional hazard model.
Vaccine effectiveness in preventing SARS-CoV2 infections is 85.5% (95%CI: 75.9-91.3) in the partially vaccinated and 84.8% (95%CI: 73.2-91.4) in the fully vaccinated. In preventing symptomatic infection effectiveness is 81.7% (95%CI: 62.7-91.0) in the partially and 87.1% (95%CI: 69.3-94.6) in the fully vaccinated. There were no COVID-19-related hospitalizations in the partially or fully vaccinated vs 15 hospitalization in the unvaccinated cohort.
Our results confirm the effectiveness of mRNA vaccines in a real-world setting in Northern Italy.
1. WHO. Weekly Operational Update on COVID-19. Issue No. 57, May 31, 2021
2. Signorelli C, Scognamiglio T, Odone A. COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population. Acta Biomed 2020; 91(3-S): 175-179.
3. Bo Y, Guo C, Lin C et al. Effectiveness of non-pharmaceutical interventions on COVID-19 transmission in 190 countries from 23 January to 13 April 2020. Int J Infect Dis 2021; 102: 247-253.
4. Kim HHS, Laurence J. COVID-19 restrictions and mental distress among American adults: evidence from Corona Impact Survey (W1 and W2). J Public Health 2020; 42(4): 704-711.
5. Polack FP, Thomas SJ, Kitchin N et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383(27): 2603-15.
6. Baden LR, El Sahly HM, Essink B et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384(5): 403-416.
7. Angel Y, Spitzer A, Henig O et al. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. JAMA 2021, May 6.
8. Fabiani M, Ramigni M, Gobbetto V, Mateo-Urdiales A, Pezzotti P, Piovesan C.
Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021. Euro Surveill 2021; 26(17): 2100420.
9. Hall VJ, Foulkes S, Saei A, Andrews N et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet 2021 8; 397(10286): 1725-1735.
10. Thompson MG, Burgess JL, Naleway AL et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR 2021; 70(13): 495-500.
11. Dagan N, Barda N, Kepten E et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med 2021; 384: 1412-1423.
12. Abo SMC, Smith SR. Is a COVID-19 Vaccine Likely to Make Things Worse? Vaccines 2020; 8(4): 761.
13. Benenson S, Oster Y, Cohen MJ. BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers. N Engl J Med 2021; 384: 1775-1777.
14. Ausl di Bologna. Report COVID 19 Comune di Bologna 17-25 aprile. https://www.ausl.bologna.it/per-i-cittadini/coronavirus/rcps (accessed on May 5, 2021)
15. RER. Ordinanza del presidente della Giunta Regionale N.68. Bologna, 30 aprile 2021.